Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments

Alex J. Turner, Cormac Sammon, Nick Latimer, Blythe Adamson, Brennan Beal, Vivek Subbiah, Keith R. Abrams and Joshua Ray ()
Additional contact information
Alex J. Turner: Putnam PHMR
Cormac Sammon: Putnam PHMR
Nick Latimer: University of Sheffield
Blythe Adamson: Flatiron Health
Brennan Beal: Flatiron Health
Vivek Subbiah: Sarah Cannon Research Institute
Keith R. Abrams: University of Warwick
Joshua Ray: F. Hoffmann-La Roche Ltd

PharmacoEconomics, 2024, vol. 42, issue 2, No 4, 165-176

Abstract: Abstract Internal validity is often the primary concern for health technology assessment agencies when assessing comparative effectiveness evidence. However, the increasing use of real-world data from countries other than a health technology assessment agency’s target population in effectiveness research has increased concerns over the external validity, or “transportability”, of this evidence, and has led to a preference for local data. Methods have been developed to enable a lack of transportability to be addressed, for example by accounting for cross-country differences in disease characteristics, but their consideration in health technology assessments is limited. This may be because of limited knowledge of the methods and/or uncertainties in how best to utilise them within existing health technology assessment frameworks. This article aims to provide an introduction to transportability, including a summary of its assumptions and the methods available for identifying and adjusting for a lack of transportability, before discussing important considerations relating to their use in health technology assessment settings, including guidance on the identification of effect modifiers, guidance on the choice of target population, estimand, study sample and methods, and how evaluations of transportability can be integrated into health technology assessment submission and decision processes.

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-023-01323-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:42:y:2024:i:2:d:10.1007_s40273-023-01323-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-023-01323-1

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().